Novel Colitis Immunotherapy Targets Bin1 and Improves Colon Cell Barrier Function.

Area of Science:

• Gastroenterology
• Immunology
• Drug Discovery

Background:

• Ulcerative colitis (UC) involves colonic epithelial barrier defects and inflammation, increasing colorectal cancer risk.
• Current UC treatments have side effects and variable efficacy, necessitating improved therapeutic strategies.
• Genetic evidence suggests Bin1 (Bridging Integrator 1) plays a role in UC pathogenicity.

Purpose of the Study:

• To investigate Bin1 (Bridging Integrator 1) targeting as a potential therapeutic option for ulcerative colitis (UC).
• To provide preclinical proof of concept for a Bin1-targeting monoclonal antibody (mAb) in experimental colitis.

Main Methods:

• Mice with experimental colitis were treated with a single dose of Bin1 mAb.
• Subsequent oral administration of DSS (dextran sulfate sodium) in water induced colitis.
• In vitro studies utilized human Caco-2 cells to assess antibody effects on barrier function.

Main Results:

• Bin1 mAb administration significantly reduced colitis morbidity in a mouse model.
• Treated mice showed fewer mucosal lesions, preserved lymphoid follicle integrity, and reduced immune cell infiltration compared to controls.
• In vitro, Bin1 antibody improved tight junction protein expression and enhanced barrier function in Caco-2 cells.

Conclusions:

• Bin1 monoclonal antibody (mAb) therapy demonstrates potential for treating ulcerative colitis (UC).
• This approach supports mucosal barrier function and protects lymphoid follicle integrity.
• Bin1 mAb may offer a novel strategy for UC treatment and potentially reduce colorectal cancer risk.